home / endocrinology / 2025
Therapeutic Area
2025
Presentation
A New Cause of Diabetes That Affects ~1.25M Americans: Who Woulda Thought?
American Diabetes Association
2025
PresentationDesign of the CATALYST Trial and Prevalence Results
American Diabetes Association
2025
PresentationFinal Results of the CATALYST Trial
American Diabetes Association
2025
PresentationCATALYST Implications—A New Paradigm for Understanding and Treating Type 2 Diabetes
American Diabetes Association
2025
PresentationMifepristone, a Glucocorticoid Receptor Antagonist, Reduced HbA1c and Body Weight in Difficult-to-control Type 2 Diabetes with Hypercortisolism: The CATALYST Prevalence and Treatment Trial
European Association for the Study of Diabetes
2025
PresentationDifficult-to-Control Type 2 Diabetes and a Post-Dexamethasone Suppression Test Cortisol of 1.2–1.8 µg/dL: Findings From a Large Prospective Study
European Association for the Study of Diabetes
2025
PosterFinal Results of the CATALYST Trial
Association of Diabetes Care & Education Specialists
2025
PosterCharacterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2–1.8, and >1.8 μg/dL: Findings From the CATALYST Part 1 Study
Association of Diabetes Care & Education Specialists
2025
PosterThe Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension
Annual Meeting of The Endocrine Society
2025
PosterEfficacy and Safety of Relacorilant in Individuals With Adrenal Hypercortisolism: Results From the Phase 3 GRACE and GRADIENT Studies
Annual Meeting of The Endocrine Society
2025
PresentationEffects of Relacorilant on Body Weight and Body Composition in Patients With Endogenous Hypercortisolism in the Phase 3 GRACE and GRADIENT Studies
Annual Meeting of The Endocrine Society
2025
PosterEffects of Relacorilant on Pituitary Tumor Volume in Patients With Cushing Disease: Results From the Phase 3 GRACE Study
Pituitary Society Congress
2025
PosterThe Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension
Heart in Diabetes
2025
PosterHigh Medication and Cardiovascular Disease Burden in Individuals With Difficult-to-Control Type 2 Diabetes: Clinical Characteristics From the CATALYST Study
Heart in Diabetes
2025
PosterEfficacy and Safety of Relacorilant in Patients With Adrenal Hypercortisolism: Results From a Phase 3 Study
American Association of Clinical Endocrinology
2025
PosterCharacterization of Patients With Difficult-to-Control Type 2 Diabetes and a Post–Dexamethasone Suppression Test Cortisol of 1.2–1.8 μg/dL: Findings From a Large Prospective Study
American Association of Clinical Endocrinology
2025
PosterA Comprehensive Safety Assessment of Relacorilant: Insights From Phase 2 and Phase 3 Trials in Patients With Endogenous Hypercortisolism
American Association of Clinical Endocrinology
2025
PosterClinical Learnings Based on a Case Series: Considerations for Identifying and Treating Hypercortisolism in Patients with Diabetes
American Association of Clinical Endocrinology
2025
PosterMedical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
European Congress of Endocrinology
2025
PosterOpen-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis
American Association of Clinical Endocrinology - Middle East & North Africa
2025